HBV Currently Lacks a Curative Treatment
Hepatitis B is a leading cause of morbidity in the US and death globally, with no current curative options
> 1,000,000
cHBV infections in the US
> 300 million
cHBV infections globally
15% to 40% of patients
with HBV infections may develop complications, such as cirrhosis, liver failure, or liver cancer, which account for the majority of HBV-related deaths.
Current HBV treatments require life-long chronic treatment that may result in viral suppression by reducing circulating HBV DNA, but these therapies do not eradicate HBV cccDNA and therefore rarely lead to functional cure.
PBGENE-HBV:
ARCUS Uniquely Targets HBV
by eliminating cccDNA and inactivating integrated HBV DNA
Current Therapeutic Strategies
are limited and do not target the root cause of disease – viral replication
HBV Mechanism of Infection